Unmasking Neurotrophic Keratitis: Diagnosing and Treating All Stages (Archived CME Webcast)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Neurotrophic keratitis (NK) is a degenerative corneal condition due to decreased or absent sensory corneal innervation. Early diagnosis can be challenging. Optimal treatment of all stages of NK is crucial for restoring epithelial integrity, mitigating progression of corneal damage, and preventing recurrent defects. This case-based educational activity can help “unmask” potential best practices in the diagnosis and treatment of all stages of NK.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Integrate evaluation of corneal sensitivity into routine assessment of ocular surface disease
- Select treatment strategies for patients diagnosed with any stage of neurotrophic keratitis
Faculty
Lisa M. Nijm, MD, JD (Chair) Assistant Professor of Ophthalmology University of Illinois Eye and Ear Infirmary Chicago, Illinois Founder and Medical Director Warrenville EyeCare and LASIK Center Warrenville, Illinois | |
W. Barry Lee, MD, FACS | |
Leslie E. O’Dell, OD, FAAO |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
W. Barry Lee, MD, has no relevant commercial relationships to disclose.
Lisa M. Nijm, MD, JD, is a consultant for Alcon, Allergan, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TruKera Medical, Thea Pharmaceuticals Limited, and Visus Therapeutics; is an advisory board member of Alcon, Allergan, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, and Trukera Medical; is on the speakers bureau for Allergan, Bausch & Lomb Incorporated, Horizon Therapeutics plc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Ocular Therapeutix, Inc; and has stock options in TruKera Medical that have not been exercised.
Leslie E. O’Dell, OD, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Eye Eco Inc, Eyedetec Medical, Inc, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Allergan, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and has stock options that have not been exercised in Èssiri Labs and Eyedetec Medical, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dompé US, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.
©2023 MedEdicus LLC. 298.2